



# Chromophobe Renal Cell Carcinoma

TCGA KICH AWG

Chairs: Chad Creighton, W. Kim Rathmell



# Introduction

- Chromophobe renal cell carcinoma (ChRCC) represents ~5% of cancers arising from the kidney nephron
- Due in part to its relative rarity, this disease has been understudied at the molecular level
- Comprehensively profiled by TCGA, as the first of its Rare Tumor Projects



# Data summary

<b>Data Type</b>	<b>Platforms</b>	<b>Cases</b>	<b>Data access</b>
Whole exome DNA sequence	Illumina	66	Controlled
Whole genome DNA sequence	Illumina	50	Controlled
Mitochondria DNA sequence	Illumina (LR-PCR)	61	Controlled
DNA copy number/genotype	Affymetrix SNP 6	66	Controlled
mRNA expression	Illumina	66	Controlled - BAM files Open - expression files
miRNA expression	Illumina	66	Controlled - BAM files Open - expression files
CpG DNA methylation	Illumina 450K	66	Open

66 tumor cases for comprehensive profiling

50 cases with whole genome sequencing

61 cases with mitochondria genome sequencing

# Data summary

Data Type	Platforms	Cases	Data access
Whole exome DNA sequence	Illumina	66	Controlled
Whole genome DNA sequence	Illumina	50	Controlled
Mitochondria DNA sequence	Illumina (LR-PCR)	61	Controlled
DNA copy number/genotype	Affymetrix SNP 6	66	Controlled
mRNA expression	Illumina	66	Controlled - BAM files Open - expression files
miRNA expression	Illumina	66	Controlled - BAM files Open - expression files
CpG DNA methylation	Illumina 450K	66	Open

66 tumor cases for comprehensive profiling

**50 cases with whole genome sequencing**

61 cases with mitochondria genome sequencing

# Data summary

Data Type	Platforms	Cases	Data access
Whole exome DNA sequence	Illumina	66	Controlled
Whole genome DNA sequence	Illumina	50	Controlled
Mitochondria DNA sequence	Illumina (LR-PCR)	61	Controlled
DNA copy number/genotype	Affymetrix SNP 6	66	Controlled
mRNA expression	Illumina	66	Controlled - BAM files Open - expression files
miRNA expression	Illumina	66	Controlled - BAM files Open - expression files
CpG DNA methylation	Illumina 450K	66	Open

66 tumor cases for comprehensive profiling

50 cases with whole genome sequencing

**61 cases with mitochondria genome sequencing**




# Somatic alterations (copy and whole exome)

# DNA copy alterations

CCRCC


ChRCC



DNA copy alteration  
loss   gain



# Somatically mutated genes









# DNA methylation and RNA expression



# DNA methylation

low  high

64,000 differential loci in total



Widespread differences between ChRCC and CCRCC

Shen H  
Laird P

**normal**


**CCRCC**

**ChRCC**

# Anatomy of the kidney nephron

proximal


distal



# Anatomy of the kidney nephron

proximal

distal




CCRCC?

ChRCC?



# Gene expression atlas of the kidney nephron



Published mRNA profiling dataset of micro-dissected regions (mouse and human)

**proximal**

**distal**

Cheval et al.  
PLOS One 2012



# ChRCC versus CCRCC expression differences reflect distal versus proximal nephron

## TCGA Kidney cancer


CCRCC

ChRCC

Kidney nephron atlas

human kidney

mouse kidney



Glom  
S1 **proximal**  
S3  
mTAL  
cTAL **distal**  
DCT  
CCD  
OMCD

Glom  
S1 **proximal**  
S3  
mTAL  
cTAL **distal**  
DCT  
CCD  
OMCD


inter-profile correlation





# Mitochondrial DNA alterations

# mtDNA somatic mutations in ChRCC



Muzny D,  
Buhay C  
Wang M


**Red**, affects  
protein coding

Events with >50%  
heteroplasmy shown



**Red**, high in ChRCC  
**Blue**, low in ChRCC  
**Yellow**, mtDNA mutation

mtDNA mutations involve the electron transport chain




The Electron Transport Chain (ETC)

**Red**, high in ChRCC

**Blue**, low in ChRCC

**Yellow**, mtDNA mutation

# ChRCC relies upon oxidative phosphorylation




The Electron Transport Chain (ETC)

**Red**, high in ChRCC

**Blue**, low in ChRCC

**Yellow**, mtDNA mutation

# ChRCC relies upon oxidative phosphorylation




**The Electron Transport Chain (ETC)**



# Whole Genome Analysis

# Kataegis observed in ChRCC



Davis C, Wheeler D




# mRNA

## correlates of kataegis

Creighton C,  
Davis C

### n=50 ChRCC

Includes TERT




Cases with  
kataegis (n=3)





n=50 ChRCC



Structural breakpoints within TERT promoter region

Copy gain 

Copy loss 

Breakpoint **X**

Davis C



# Structural variants associated with TERT promoter region by WGS analysis

<i>case</i>	<b>breakpoint A</b>			<b>breakpoint B</b>			<i>event type</i>
	<i>chr:pos</i>	<i>ori</i>	<i>gene</i>	<i>chr:pos</i>	<i>ori</i>	<i>gene</i>	
KL-8341	5:1116986	-1		5:1296148	1	TERT PM	tandem dup.
KN-8435	5:272199	1	PDCD6	5:1296716	1	TERT PM	inversion
KM-8438	5:1348783	-1		5:1295372	1	TERT PM	deletion
KL-8346	5:1125430	-1		5:1295604	1	TERT PM	tandem dup.
KL-8323	5:49560803	1		5:1299528	-1	TERT PM	tandem dup.
KL-8323	5:49563017	-1		5:1297603	1	TERT PM	del-insertion
KM-8443	13:52688659	1	NEK5	5:1305300	1	TERT PM	Inter-chr transl.

Davis C, Wang L, Park P


Meerkat algorithm





# TERT promoter-associated SVs correlate with high TERT expression


*TERT* expression






# TERT promoter-associated SVs correlate with high TERT expression

*TERT* expression



# Validation of TERT PM-associated SVs



KN-8435 (inversion)



CTGGGGCCGCCCTGCCTCCTGTGTGTTAATACTTCAGCATAATCTTCTGCTTCCATTTTTT

# Validation of TERT PM-associated SVs

## KN-8435 (inversion)



# Conclusions

- Comprehensive molecular analysis of a rare cancer type as a platform for discovery
- Global molecular patterns may provide clues as to a cancer's cell of origin
- mtDNA sequencing incorporated into multi-platform molecular characterization of cancer
- Discovery of recurrent genomic rearrangements involving TERT promoter region



# KICH Analysis Working Group

Chad Creighton (co-chair)	Baylor	Lisa Henske	Harvard
Kimryn Rathmell (co-chair)	UNC	Donna Muzny	Baylor
Hui Shen	USC	Pheroze Tamboli	MDACC
David Kwiatkowski	Harvard	Ari Hakimi	MSKCC
Toni Chouieri	Harvard	James Hsieh	MSKCC
Caleb Davis	Baylor	Victor Reuter	MSKCC
Richard Gibbs	Baylor	Christopher Ricketts	NIH/NCI
David Wheeler	Baylor	W. Marston Linehan	NIH/NCI
Maggi Morgan	Baylor	Laura Schmidt	NIH/NCI
Larry Donehower	Baylor	Maria Merino	NIH/NCI
Preethi Gunaratne	Baylor	Brian Shuch	NIH/NCI
Gordon Robertson	BCGSC	Satish Tickoo	MSKCC
Andy Chu	BCGSC	Billy Kim	UNC
Andrew Mungall	BCGSC	Eric Wallen	UNC
Payal Sipahimalani	BCGSC	Angie Smith	UNC
Andrew Cherniack	Broad	Sahil Seth	MDACC
Matthew Meyerson	Broad	Catherine Fahey	UNC
Raju Kucherlapati	Harvard	Kate Hacker	UNC
Sabina Signoretti	Harvard	Gyan Bhanot	Rutgers
Lixing Wang	Harvard	Peter Laird	USC
Peter Park	Harvard		

STAFF: Jean Claude Zenklusen, Ina Felau, Lindsay Lund, + NCI Senior Leadership; NHGRI Senior Leadership